Gene · 7468
NSD2: nuclear receptor binding SET domain protein 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. NSD2: nuclear receptor binding SET domain protein 2. Genes, record 7468. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/7468
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O96028 | Histone-lysine N-methyltransferase NSD2 | 1,365 | 22 | Ensembl, GeneID, HGNC |
Source UniProt
Patents70
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 69943 | O96028 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 69944 | O96028 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 69945 | O96028 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 69951 | O96028 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 10588 | O96028 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 10946 | O96028 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 15837 | O96028 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 10946 | O96028 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 10588 | O96028 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 15837 | O96028 | Espacenet |
1 to 10 of 70
See all 70 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,474
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | NSD2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 37 | 2025 |
| P50CA186781 | Mayo Clinic Multiple Myeloma SPORE | 23 | 2025 |
| P01CA155258 | Integrative Oncogenomics of Multiple Myeloma | 15 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 13 | 2025 |
| P30CA060553 | The Robert H. Lurie Comprehensive Cancer Center | 12 | 2025 |
| I01BX001584 | Molecular Manipulation to Enhance Anti-Myeloma Response | 8 | 2025 |
| P30CA016087 | Cancer Center Support Grant | 8 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 8 | 2025 |
| P30CA086862 | Cancer Center Support Grant | 8 | 2025 |
| R01AI118891 | Viral modulation of epitranscriptomic mechanisms | 8 | 2025 |
1 to 10 of 1,474Source NIH's project files
See all 1,474 nih grantsPapers2,351
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| NSD2 drives triple-negative breast cancer progression via ATAD3A-dependent senescence. | Cell Signal | 2026 | 42822681 | PubTator, text mining | PubMed |
| NSD Histone Methyltransferases in Solid Tumors: Biological Functions, Oncogenic Mechanisms and Therapeutic Targeting. | Int J Mol Sci | 2026 | 42794546 | PubTator, text mining | PubMed |
| Degrading NSD2 rewires the myeloma niche. | Blood | 2026 | 42783363 | PubTator, text mining | PubMed |
| Rauch-Steindl syndrome: intrauterine phenotype and diagnostic utility of prenatal exome sequencing. | BMJ Case Rep | 2026 | 42754354 | PubTator, text mining | PubMed |
| Genomic Characterization of ETV6::RUNX1-Positive Childhood B-ALL in a Chinese Cohort: Novel Fusion Partners, Co-Occurring Mutations, and Risk-Stratifying Biomarkers. | Pediatr Blood Cancer | 2026 | 42720515 | PubTator, text mining | PubMed |
| Phenotypes of Hereditary Diseases Associated With Rauch-Steindl Syndrome. | Hum Mutat | 2026 | 42694379 | PubTator, text mining | PubMed |
| Expanding the Molecular Spectrum of Papillary Renal Neoplasm With Reverse Polarity: A Report of Two Cases and a Literature Review. | Cureus | 2026 | 42602752 | PubTator, text mining | PubMed |
| Alternative Splicing in Cyclin-Dependent Kinase 4/6 Inhibitor Resistance in Estrogen Receptor-Positive Breast Cancer. | Drug Dev Res | 2026 | 42574086 | PubTator, text mining | PubMed |
| Degraders of histone lysine methyltransferases: Progress, challenges, and opportunities. | Drug Discov Today | 2026 | 42542162 | PubTator, text mining | PubMed |
| NSD2 is a critical regulator of Erastin-induced ferroptosis in keratinocytes. | Free Radic Biol Med | 2026 | 42462913 | PubTator, text mining | PubMed |
1 to 10 of 2,351
See all 2,351 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/7468
GET https://conductscience.org/api/genes/v1/7468/patents?page=2